Layer 1

Legal view: EU law will change the way you dispense

"Regardless of whether the UK remains in the EU, the risk of counterfeits will only be able to dealt with on this Europe-wide basis"

Lawyer David Reissner explains how every pharmacy will be affected by a new anti-counterfeiting law

In February, the European Commission announced that the falsified medicines directive (FMD) will become law across Europe on February 9, 2019.

The FMD aims to prevent counterfeit medicines entering the supply chain. The most common counterfeits are for the treatment of sexual dysfunction, heartburn and cancer. For example, fake Avastin, which entered the US supply chain in 2012. 

Under the forthcoming EU law, prescription medicines will have a unique identifier in the form of a barcode that recognises the product name, pharmaceutical form, strength, pack size, batch number and expiry date.

Each pack will also have an anti-tampering device and will need to be checked in pharmacies at the time of supply. Every pharmacy must contain a scanner, connected to a repository held by the marketing authorisation holder. If a counterfeit product is scanned, an alarm will be triggered and the marketing authorisation holder will have to notify the authorities. 

The law may mean that it becomes impossible to supply imported medicines in the UK if they can be sold over the counter in their country of origin, because they will not have the anti-tamper device and barcode.

If the scanner identifies the medicine as genuine, the pharmacy must “decommission” the barcode, probably by selecting an on-screen option. Once decommissioned, it will not be possible to resupply the item. 

There might be occasions when, after scanning and decommissioning, a patient does not receive the medication. This might happen if a patient is not at home to take delivery, or the wrong item was selected and then not supplied.

Decommissioned medicines cannot be returned to stock. However, pharmacies will be able to reverse the decommissioning if no supply has been made and the decommissioning is done on the same premises within 10 days. If a split pack is used, the pharmacy must verify the pack when it is first opened, and then decommission the pack.

If technical problems prevent scanning, a supply may be made. The pharmacy will be required to make a record of the barcode and verify and decommission it as soon as the technical problem has been resolved. 

If a pharmacy suspects that a product has been falsified or tampered with, the Medicines and Healthcare products Regulatory Authority (MHRA) must be notified – and the product must not be supplied.

In just under three years' time, the risk of counterfeit medicines will only be able to dealt with on this Europe-wide basis – regardless of whether the UK remains in the European Union or not.

David Reissner is senior healthcare partner at law firm Charles Russell Speechlys ([email protected])

More from David Reissner


How do you think the anti-counterfeit law will affect you? 

We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information


N A, Non healthcare professional

How bad is the counterfeit medicines problem? To combat it, is the answer really for every package to be scanned just before it gets to the patient? This stuff isn't mentioned in the DH hub and spoke consultation, and it will surely have a huge impact on the viability of any hub and spoke model? Why David do you say that the problem will have to be dealt with Europe wide in a few years time - is the issue getting worse? This particular legislation will only come in to force if we stay in the EU?

Judith Hible, Community pharmacist

So all the uncollected medicines will not be able to be reissued? Roll-on retirement

Susan M Shepherd, Community pharmacist

Only really works if you have original pack dispensing, as happens in many countries on the continent. Systems need to be devised to deal with items returned to stock where they are not supplied to the patient in the uk. There are many stages in the UK dispensing process that do not appear on the continent. In places like Belgium the item is scanned at the point it is given to the patient. UK computer systems need to cope with a different way of working, particularly if we are to go to hub and spoke, so beloved of our government.

Angela Channing, Community pharmacist

As if we haven't got enough to do!! 

M Elnemy, Non healthcare professional


Harry Tolly, Pharmacist


Already happening in Belgium from way back in 2006. Way ahead of the game.


Job of the week

Support Pharmacist
Queen Elizabeth Hospital and Heartl
up to £47,500 dependent on hours (30-40 hours flexible)